Cargando…

Advanced Targeted, Cell and Gene-Therapy Approaches for Pediatric Hematological Malignancies: Results and Future Perspectives

Despite the survival of pediatric patients affected by hematological malignancies being improved in the last 20 years by chemotherapy and hematopoietic stem cell transplantation, a significant amount of patients still relapses. Treatment intensification is limited by toxic side effects and is constr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Magnani, Chiara F., Tettamanti, Sarah, Maltese, Francesca, Turazzi, Nice, Biondi, Andrea, Biagi, Ettore
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2013
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639447/ https://www.ncbi.nlm.nih.gov/pubmed/23641364 http://dx.doi.org/10.3389/fonc.2013.00106

Ejemplares similares

Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform
por: Magnani, Chiara F., et al.
Publicado: (2016)

Liquid biopsy in hematological malignancies: current and future applications
por: Talotta, Donatella, et al.
Publicado: (2023)

New advances in leukaemia immunotherapy by the use of Chimeric Artificial Antigen Receptors (CARs): state of the art and perspectives for the near future
por: Biagi, Ettore, et al.
Publicado: (2011)

Advances in the Study of circRNAs in Hematological Malignancies
por: Du, Jingyi, et al.
Publicado: (2022)

Case Report: Infectious prophylaxis in hematological malignancies
por: Passucci, Mauro, et al.
Publicado: (2023)

Lessons From Pediatric MDS: Approaches to Germline Predisposition to Hematologic Malignancies
por: Avagyan, Serine, et al.
Publicado: (2022)

Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies
por: Tasian, Sarah K., et al.
Publicado: (2014)

Gene Therapy for Pediatric Cancer: State of the Art and Future Perspectives
por: Biagi, Ettore, et al.
Publicado: (2003)

CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics?
por: Tettamanti, Sarah, et al.
Publicado: (2014)

Semaphorins and Their Receptors in Hematological Malignancies
por: Wei, Li, et al.
Publicado: (2019)

WNT Signaling in Hematological Malignancies
por: Frenquelli, Michela, et al.
Publicado: (2020)

Editorial: Reviews in hematologic malignancies
por: Saraceni, Francesco, et al.
Publicado: (2022)

Checkpoint inhibition in hematologic malignancies
por: Tsumura, Aaron, et al.
Publicado: (2023)

Ferroptosis in hematological malignant tumors
por: Liu, Yong, et al.
Publicado: (2023)

Cap-Independent Translation in Hematological Malignancies
por: Horvilleur, Emilie, et al.
Publicado: (2015)

Multiple Roles of Glycans in Hematological Malignancies
por: Pang, Xingchen, et al.
Publicado: (2018)

PHF6 Mutations in Hematologic Malignancies
por: Kurzer, Jason H., et al.
Publicado: (2021)

The hedgehog pathway in hematopoiesis and hematological malignancy
por: Lemos, Tucker, et al.
Publicado: (2022)

Editorial: Epidemiological trends in hematological malignancies
por: de Lima, Marcos, et al.
Publicado: (2023)

Bone Marrow Senescence and the Microenvironment of Hematological Malignancies
por: Hellmich, Charlotte, et al.
Publicado: (2020)

Editorial: Rising Stars in Hematologic Malignancies 2021
por: Qian, Liren, et al.
Publicado: (2022)

Single-Cell Metabolomics in Hematopoiesis and Hematological Malignancies
por: Zuo, Fengli, et al.
Publicado: (2022)

Arginase: Mechanisms and Clinical Application in Hematologic Malignancy
por: Du, Zefan, et al.
Publicado: (2022)

Editorial: Linking cellular metabolism to hematological malignancies
por: He, Xiujing, et al.
Publicado: (2022)

Editorial: Measurable residual disease in hematologic malignancies
por: Buccisano, Francesco, et al.
Publicado: (2023)

Editorial: Tumour microenvironment heterogeneity in hematological malignancies
por: Deaglio, Silvia, et al.
Publicado: (2023)

Germline and somatic drivers in inherited hematologic malignancies
por: Zoller, Julian, et al.
Publicado: (2023)

Editorial: Case reports in hematological malignancies: 2022
por: Antar, Ahmad, et al.
Publicado: (2023)

Pediatric hematological malignancy: Identification of issues involved in the road to diagnosis
por: Venkatasai, Jeyaanth P., et al.
Publicado: (2017)

Crosstalk Between MYC and lncRNAs in Hematological Malignancies
por: Arman, Kaifee, et al.
Publicado: (2020)

Screening Strategies for COVID-19 in Patients With Hematologic Malignancies
por: Assi, Tarek, et al.
Publicado: (2020)

Molecular Mechanisms of Ferroptosis and Its Roles in Hematologic Malignancies
por: Zhao, Yan, et al.
Publicado: (2021)

The Role of Exosomes in the Progression and Therapeutic Resistance of Hematological Malignancies
por: Wang, Haobing, et al.
Publicado: (2022)

Role and Mechanisms of Tumor-Associated Macrophages in Hematological Malignancies
por: Xie, Yutong, et al.
Publicado: (2022)

Editorial: COVID-19 and hematological malignancies: Volume II
por: Wilde, Lindsay, et al.
Publicado: (2022)

Editorial: The management of hematologic malignancies in lower-income countries
por: Ganesan, Prasanth, et al.
Publicado: (2023)

Editorial: Deciphering the bone marrow microenvironment in hematologic malignancies
por: Wobus, Manja, et al.
Publicado: (2023)

Validation of the FACT-G7 in patients with hematologic malignancies
por: Du, Xinwen, et al.
Publicado: (2023)

Cellular immunotherapy for hematological malignancy: recent progress and future perspectives
por: Xu, Zhengli, et al.
Publicado: (2021)

Amino acids in hematologic malignancies: Current status and future perspective
por: Wang, Mengyao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s7c9elosh1r85crrmttnrh93v2